Acoramidis Reduces QoL Decline in High-Risk ATTRv-CM - Oct 12, 2026 - "'In patients with p.Val142Ile ATTRv-CM, acoramidis significantly attenuated the decline in HF-related health status and HRQoL through M30 vs placebo, with a trend toward less decline in functional capacity, complementing previously reported survival benefits of acoramidis in this high-risk population,' the researchers concluded."
Media quote
|